Hosted by: Karolinka Institutet
Cancer Core Europe Lecture: Presented by Education & Training Task Force
SPEAKER
Linda Lindström
Assoc. Professor, Principal researcher, Dept. of Oncology Pathology, Karolinska Institutet
Zoom link at
Breast cancer (BC) is a heterogeneous disease with the main fundamental difference being whether the tumour is hormone-sensitive or not, i.e. oestrogen receptor-positive (ER+) or negative (ER-). A unique feature of ER+ BC is the long-term risk of metastatic recurrence decades after initial diagnosis, and half or more of all BC metastases in this patient group will be diagnosed LATE i.e. beyond 5 - 10 years after diagnosis.
The factors underlying late risk of metastatic recurrence remain poorly understood. Current research is mainly focused on early risk, partly due to the lack of tumour samples from patients with complete longterm follow-up.
This Lecture will provide insights into Research focused on the longterm risk of metastatic disease, and how risk and endocrine treatment benefit is influenced by menopausal status and tumour biology including standard tumour markers, intra-tumour heterogeneity, and tumour microenvironment using unique clinical trials with complete longterm follow-up.
What is Cancer Core Europe (CCE)?
Cancer Core Europe is a consortium of seven leading cancer centres (www.cancercoreeurope.eu). CCEs members are driven by a strong will to reshape the cancer research model to ultimately increase the European Union’s competitiveness as a place to conduct cutting-edge research that’s translated to the clinic to deliver more personalized medicine.
What is the content and aim of the CCE Lecture?
The CCE Lecture series is a CCE-internal event, which educates and informs about state-of-the-art research within the seven centers and is aimed to increase awareness among partners about each other’s activities and potential for collaboration.
